

Screening phase C and E-arm	PART I: Standard of care: <i>Oligo - SABR</i> <i>Poly - (SAB)R</i> Day X + 1-14days (depends on total fx)	Last day Friday (72h max before Immuno.)	PART II: Immunotherapy (x6 cycles) Day Y +3 (Monday) // Y+24 days // +45 // +66 // +87 // +108	Day Y +5 (Wednesday) // Y+26 days // +47 // +68 // +89 // +110	Day Y + 7 (Friday) // Y+28 days // +49 // +70 // +91 // +112	Follow-up* (most important timepoints showed) Start counting at randomisation day (R)
Before trail inclusion (min1-5days)	Start study	Day *Y	Day Y + 3	Day Y + 5	Day Y + 7	Day R+12wks
Eligibility: known inclusion/exclusion criteria, (SAB)R, aPD(L)1 maintenance?		Last (SAB)R fx	Pre-injection	Pre-injection	Pre-injection	QOL +WHO + adverse events CT-scan
Day 1 Informed consent Demographics, medical history, physical examination, vital signs (BP, P, T) height and body weight. Assessment of concurrent therapy. Blood sampling (incl pregnancy test) Histology, collection of stratification factors, SOC baseline imaging (<6w). Evaluation of adverse events Investigator decision ECG+LVEF	Day X Start (SAB)R fx(n) Day X + <14 Follow-up visit (can be the same as on day Y)	! Blood for translational research (in case of allocation to arm E this bloodsample can be taken together with the bloodtest on first injection day)	Blood tests WHO Concurrent therapy & medication, PCM 1gr 1h prior, weight	#Blood tests QOL + WHO Concurrent therapy & medication, PCM 1gr 1h prior	#Blood tests WHO Concurrent therapy & medication, PCM 1gr 1h prior	! Blood for translational research
Day 3- ~8 (signed informed consent and Eligible conform in&exclusion)			During-3h-injection: Infusion cycle 30min (BP, T, HR, BR), Adverse events Post-injection: Infusion cycle (BP, T, HR, BR) at 30min, 1h and 2h, Adverse events	During-3h-injection: Infusion cycle 30min (BP, T, HR, BR), Adverse events Post-injection: Infusion cycle (BP, T, HR, BR) at 30min, 1h and 2h, Adverse events	During-3h-injection: Infusion cycle 30min (BP, T, HR, BR), Adverse events Post-injection: Infusion cycle (BP, T, HR, BR) at 30min, 1h and 2h, Adverse events	
Randomisation (R)			ONLY FOR ARM "E"			Day R + 24wks CT-scan QOL +WHO + adverse events
E-arm>> Plan Planning CT >> Start developing irradiation plan						Day R + 36wks CT-scan QOL +WHO + adverse events
Translational blood Stool sample + optional biopsy + archived biopsy						! Blood for translational research
Baseline QOL , Baseline WHO						Day R + 48wks //+54wks //+62wks //+70wks //+78wks QOL +WHO + adverse events CT-scan
Irradiation plan finished						

Legend - C an E-arm

X: Day were first fx of SABR will be given
Y: Last day of the last fx of SABR
R: Day were randomisation took place

CR: Complete response; disappearance all target and non-target lesions & normalization of tumour markers
PR: Partial response; at least a 30% decrease in target lesions, Non target lesions non-PD
SD: Stable disease
PD: Progressive disease; at least a 20% increase and/or new lesions

QOL: Quality of life questionnaires (C30, LC13 and EQ5D)

#Blood tests: blood test is only planned if it is the investigator's decision.

* Be aware that only most important time points are presented. Other time points e.g. 6wks interval (if SOC) are not shown.

Be aware: E-arm patients will receive FU-scans (incl contrast) during L19-IL2 cyclus. FU-scans 1.5 weeks after L19-IL2 infusion but before start new cycle!

BP: blood pressure, ECG: electrocardiogram, fx: fractions, gr: gram, h: hour, HR: heart rate, LVEF: left ventricular ejection fraction, P: puls, R: randomisation, T: temperature, WHO: world health organization Performance Status, wks: weeks.